{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lurbinectedin"]],"indication":"first-line metastatic leiomyosarcoma","name":"SaLuDo","nct_id":"NCT06088290","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=saludo-nct06088290. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SaLuDo","arms":[{"description":"Participants will receive doxorubicin and lurbinectedin intravenously (IV) every three weeks (q3wk) on Day 1 of each treatment cycle (treatment cycle = three weeks).","label":"Doxorubicin (Dose A) + Lurbinectedin (Dose B)","type":"EXPERIMENTAL"},{"description":"Participants will receive doxorubicin and lurbinectedin IV q3wk on Day 1 of each treatment cycle (treatment cycle = three weeks).","label":"Doxorubicin (Dose C) + Lurbinectedin (Dose D)","type":"EXPERIMENTAL"},{"description":"Participants will receive doxorubicin IV q3wk on Day 1 of each treatment cycle (treatment cycle = three weeks).","label":"Doxorubicin (Dose E)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-08-30","type":"ESTIMATED"},"conditions":["Leiomyosarcoma"],"enrollment":{"count":469,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lurbinectedin","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-18","lead_sponsor":"PharmaMar","official_title":"Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-08-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS by IRC","timeFrame":"Up to approximately 41 months"}],"references":[{"citation":"Cote GM, Chawla SP, Demetri G, Kasper B, Jones RL, Broto JM, Wooley J, Weiss MC, Tafuto S, Badalamenti G, Carrasco I, Peinado P, Blay JY, Boggio G, Fernandez C, Nieto A, Kahatt C, Alfaro V, Le Cesne A. SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncol. 2025 Apr;21(8):943-951. doi: 10.1080/14796694.2025.2463798. Epub 2025 Feb 11.","pmid":"39932221","type":"DERIVED"}],"start_date":{"date":"2023-09-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","url":"https://clinicaltrials.gov/study/NCT06088290"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/saludo-nct06088290"}